Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Ledford, Kelly J ^a   Murphy, Nikki ^a   Zeigler, Frank ^a   Bartel, Ronnda L ^a   Tubo, Ross ^a  

^a Aastrom Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; CCL1 CHEMOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; IXMYELOCEL T; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 3; NITRATE; NITRIC OXIDE; OSTEOPROTEGERIN; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BECAPLERMIN; CD45 ANTIGEN; NITRIC ACID DERIVATIVE; PLATELET DERIVED GROWTH FACTOR B; TUMOR NECROSIS FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD FLOW; CAPILLARY DENSITY; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HIND LIMB ISCHEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIMB ISCHEMIA; NONHUMAN; PARACRINE SIGNALING; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; SURVIVAL; TISSUE REGENERATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BIOLOGICAL THERAPY; BIOSYNTHESIS; BLOOD; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; HINDLIMB; ISCHEMIA; MACROPHAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION; VASCULARIZATION; WOUND HEALING;

RATTUS;

ANIMALS; ANTIGENS, CD45; APOPTOSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-10; ISCHEMIA; MACROPHAGES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PARACRINE COMMUNICATION; PROTO-ONCOGENE PROTEINS C-SIS; RATS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84928550118     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-015-0007-3     Document Type: Article

References (40)

1. Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res. 2013;112:1288-302.
2. Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD, Longcore AT, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther. 2012;20:1280-6.
3. Norgren L, Hiatt WR, Dormandy JA, Hirsch AT, Jaff MR, Diehm C, et al. The next 10 years in the management of peripheral artery disease: perspectives from the 'PAD 2009' Conference. Eur J Vasc Endovasc Surg. 2010;40:375-80.
4. Terry T, Chen Z, Dixon RA, Vanderslice P, Zoldhelyi P, Willerson JT, et al. CD34(+)/M-cadherin(+) bone marrow progenitor cells promote arteriogenesis in ischemic hindlimbs of ApoE(-)/(-) mice. PLoS One. 2011;6:e20673.
5. Burdon TJ, Paul A, Noiseux N, Prakash S, Shum-Tim D. Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential. Bone Marrow Res. 2011;2011:207326.
6. Sun Q, Zhang Z, Sun Z. The potential and challenges of using stem cells for cardiovascular repair and regeneration. Genes Dis. 2014;1:113-9.
7. Bartel RL, Cramer C, Ledford K, Longcore A, Parrish C, Stern T, et al. The Aastrom experience. Stem Cell Res Ther. 2012;3:26.
8. Ledford KJOJ, Parrish C, Zeigler F, Bartel RL. Ixmyelocel-T, an expanded multicellular therapy, contains a population of alternatively activated macrophages. Stem Cell Res Ther. 2013;6:134.
9. Powell RJ, Comerota AJ, Berceli SA, Guzman R, Henry TD, Tzeng E, et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg. 2011;4:132.
10. Gastens MH, Goltry K, Prohaska W, Tschope D, Stratmann B, Lammers D, et al. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy. Cell Transplant. 2007;16:685-96.
11. Chang YL, Chen CL, Kuo CL, Chen BC, You JS. Glycyrrhetinic acid inhibits ICAM-1 expression via blocking JNK and NF-kappaB pathways in TNF-alpha-activated endothelial cells. Acta Pharmacol Sin. 2010;31:546-53.
12. Kang DG, Moon MK, Lee AS, Kwon TO, Kim JS, Lee HS. Cornuside suppresses cytokine-induced proinflammatory and adhesion molecules in the human umbilical vein endothelial cells. Biol Pharm Bull. 2007;30:1796-9.
13. Davis PA, Polagruto JA, Valacchi G, Phung A, Soucek K, Keen CL, et al. Effect of apple extracts on NF-kappaB activation in human umbilical vein endothelial cells. Exp Biol Med (Maywood). 2006;231:594-8.
14. Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A. 2005;102:10999-1004.
15. Ledford KJ, Zeigler F, Bartel RL. Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages. Stem Cell Res Ther. 2013;4:134.
16. Shen B, Gao L, Hsu YT, Bledsoe G, Hagiwara M, Chao L, et al. Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol. 2010;299:H1419-27.
17. He S, Li M, Ma X, Lin J, Li D. CD4+ CD25+ Foxp3+ regulatory T cells protect the proinflammatory activation of human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2010;30:2621-30.
18. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008;118:58-65.
19. Waxman AB, Mahboubi K, Knickelbein RG, Mantell LL, Manzo N, Pober JS, et al. Interleukin-11 and interleukin-6 protect cultured human endothelial cells from H2O2-induced cell death. Am J Respir Cell Mol Biol. 2003;29:513-22.
20. Medina RJ, O'Neill CL, O'Doherty TM, Knott H, Guduric-Fuchs J, Gardiner TA, et al. Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol Med. 2011;17:1045-55.
21. Kwon YW, Heo SC, Jeong GO, Yoon JW, Mo WM, Lee MJ, et al. Tumor necrosis factor-alpha-activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. Biochim Biophys Acta. 1832;2013:2136-44.
22. Zhang H, Ning H, Banie L, Wang G, Lin G, Lue TF, et al. Adipose tissue-derived stem cells secrete CXCL5 cytokine with chemoattractant and angiogenic properties. Biochem Biophys Res Commun. 2010;402:560-4.
23. Bousquenaud M, Schwartz C, Leonard F, Rolland-Turner M, Wagner D, Devaux Y. Monocyte chemotactic protein 3 is a homing factor for circulating angiogenic cells. Cardiovasc Res. 2012;94:519-25.
24. Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost. 2013;109:391-8.
25. Kanzler I, Tuchscheerer N, Steffens G, Simsekyilmaz S, Konschalla S, Kroh A, et al. Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res Cardiol. 2013;108:310.
26. Freitas-Andrade M, Carmeliet P, Charlebois C, Stanimirovic DB, Moreno MJ. PlGF knockout delays brain vessel growth and maturation upon systemic hypoxic challenge. J Cereb Blood Flow Metab. 2012;32:663-75.
27. Trouillon R, Kang DK, Park H, Chang SI, O'Hare D. Angiogenin induces nitric oxide synthesis in endothelial cells through PI-3 and Akt kinases. Biochemistry. 2010;49:3282-8.
28. Benslimane-Ahmim Z, Poirier F, Delomenie C, Lokajczyk A, Grelac F, Galy-Fauroux I, et al. Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis. 2013;16:575-93.
29. Seeger FH, Rasper T, Koyanagi M, Fox H, Zeiher AM, Dimmeler S. CXCR4 expression determines functional activity of bone marrow-derived mononuclear cells for therapeutic neovascularization in acute ischemia. Arterioscler Thromb Vasc Biol. 2009;29:1802-9.
30. Lahteenvuo J, Rosenzweig A. Effects of aging on angiogenesis. Circ Res. 2012;110:1252-64.
31. Fang WT, Li HJ, Zhou LS. Protective effects of prostaglandin E1 on human umbilical vein endothelial cell injury induced by hydrogen peroxide. Acta Pharmacol Sin. 2010;31:485-92.
32. Dreger H, Westphal K, Wilck N, Baumann G, Stangl V, Stangl K, et al. Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2. Cardiovasc Res. 2010;85:395-403.
33. Lefevre J, Michaud SE, Haddad P, Dussault S, Menard C, Groleau J, et al. Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: effect on endothelial progenitor cells and nitric oxide. FASEB J. 2007;21:3845-52.
34. Liu DH, Chen YM, Liu Y, Hao BS, Zhou B, Wu L, et al. Rb1 protects endothelial cells from hydrogen peroxide-induced cell senescence by modulating redox status. Biol Pharm Bull. 2011;34:1072-7.
35. Ou HC, Lee WJ, Lee IT, Chiu TH, Tsai KL, Lin CY, et al. Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol. 2009;106:1674-85.
36. Zapolska-Downar D, Naruszewicz M. Propionate reduces the cytokine-induced VCAM-1 and ICAM-1 expression by inhibiting nuclear factor-kappa B (NF-kappaB) activation. J Physiol Pharmacol. 2009;60:123-31.
37. Bartel RL, Booth E, Cramer C, Ledford K, Watling S, Zeigler F. From bench to bedside: review of gene and cell-based therapies and the slow advancement into phase 3 clinical trials, with a focus on Aastrom's ixmyelocel-T. Stem Cell Rev. 2013;9:373-83.
38. Dao M, Tate CC, McGrogan M, Case CC. Comparing the angiogenic potency of naive marrow stromal cells and Notch-transfected marrow stromal cells. J Transl Med. 2013;11:81.
39. Shireman PK. The chemokine system in arteriogenesis and hind limb ischemia. J Vasc Surg. 2007;45:A48-56.
40. Fung E, Helisch A. Macrophages in collateral arteriogenesis. Front Physiol. 2012;3:353.